Glenmark to conduct ‘FAITH’ trials
With the number of COVID-19 patients rising in India, Glenmark Pharmaceuticals Ltd., has announced a new randomised, open-label study to test the combined efficacy of two antiviral drugs — Favipiravir and Umifenovir — as a potential COVID-19 treatment strategy.
- With the number of COVID-19 patients rising in India, Glenmark Pharmaceuticals Ltd., has announced a new randomised, open-label study to test the combined efficacy of two antiviral drugs — Favipiravir and Umifenovir — as a potential COVID-19 treatment strategy.
- The two antiviral drugs have different mechanisms of action, and their combination may demonstrate improved treatment efficacy by effectively tackling high viral loads in patients during early stages of the disease.
- The new combination clinical trial will be called FAITH – (FA vipiravir plus Um I fenovir (efficacy and safety) Trial in Indian Hospital setting).
Courses
Study Notes
Home
Resources
More